

T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

30 June 2025

Dear Healthcare Professional,

DRUG ALERT CLASS 3 – No 31 2025 – CLASS 3 MEDICINES RECALL – ACTION WITHIN 5 DAYS – WOCKHARDT UK LTD – TAMOXIFEN 20MG FILM-COATED TABLETS

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team



Medicines & Healthcare products
Regulatory Agency

MEDICINES RECALL

CLASS 3 MEDICINES RECALL, EL(25)A/31

Action within 5 days

Issued 30 June 2025

Distribute to Pharmacy/Wholesaler Level

MARKETING AUTHORISATION HOLDER (MAH)

Wockhardt UK Ltd (MA Holder)

MEDICINE DETAILS

Medicine name: Tamoxifen 20mg Film-Coated Tablets

PL 29831/0195

Active Ingredient: tamoxifen citrate

SNOMED code: 659711000001107

GTIN: 15012727402205

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
HZ10030	30/04/2027	30	22/08/2024

Background

Wockhardt UK Limited is recalling the above batch as a precautionary measure following the identification of a dissolution failure during stability testing.

Advice for Healthcare Professionals:

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for Healthcare Professionals to Provide to Patients:

Patients should continue to take medicines as prescribed by your healthcare professional. The recall is being actioned at the pharmacy and wholesaler level as a precautionary measure. No complaints of harm or lack of efficacy have been received from patients regarding this batch.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Additional information:

For medical information enquiries please email drug.safety@wockhardt.co.uk, or telephone 01978 661261 and ask for 'drug safety'.

For stock control enquiries please email group_uk_csu@wockhardt.co.uk, or telephone 01978 661261 and ask for 'customer services'.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk